ADELAIDE, Australia – 25/03/2022
Aucentra Therapeutics (https://www.aucentra.com/) is pleased to announce the appointment of Mr. Joe Bayer as Chief Executive Officer to lead the company in its growth and commercial phase. Aucentra Therapeutics is a clinical stage Australian Biotech company with a pipeline of innovative therapeutics targeting the most difficult to treat cancer types including brain tumor and pancreatic cancer.
Joe has 30 years’ experience in senior executive roles in the healthcare, consumer products and pharmaceutical industries both in domestic and international markets. He brings to the Aucentra team extensive experience in global executive leadership and corporate governance. His wide skillset covers expertise in business strategy, M&A activity and business operations with a specialized focus in the commercialisation of healthcare and pharmaceutical products.
He has acted in a wide variety of CEO and Board positions with listed and private companies. Prior to his appointment at Aucentra, Joe worked with a number of SME’s to assist in capital funding and strategic advice. He also served as Executive Chairman at Innovaderma Plc, a London Stock Exchange listed healthcare company where he oversaw the development of the business from its early stages through to acquisitions and the UK listing and prior as CEO of Kain Lawyers, a leading Adelaide corporate and commercial law firm. Joe has previously held the positions of Executive General Manager at Faulding and Mayne Pharma responsible for Australia and Southeast Asia, and general management positions at Fletcher Building and CSR based throughout Australia and Asia.
Joe is graduate of the University of South Australia, Fellow Certified Practising Accountants (FCPA), graduate of the Australian Institute of Company Directors (GAICD) and alumni of the Australian Graduate School of Management.
Professor Shudong Wang, Founder and Director, Aucentra Therapeutics, said
“With his impressive track record in global executive leadership, corporate governance, and commercialisation, Joe brings valuable expertise and knowledge to the company. His appointment as CEO will help Aucentra to realize its potential and progress towards the commercialisation of our pipeline drug programs”
Joe Bayer, said
“I am delighted to be leading Aucentra at this exciting stage of the company’s development. The company is extremely well placed with Professor Wang and the world class research group complimenting a great commercial team. The robust pipeline of cancer drugs in both pre-clinical and clinical phases positions Aucentra to be a world leader in providing therapies for difficult to treat cancers, something of which I have great passionate for”
Recent Comments